hexahydro-1,3,5-triethyl-s-triazine: bacteriostatic & fungistatic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 24512 |
| CHEMBL ID | 3188974 |
| SCHEMBL ID | 407168 |
| MeSH ID | M0075898 |
| Synonym |
|---|
| s-triazine, 1,3,5-triethylhexahydro- |
| 1,3,5-triazine, 1,3,5-triethylhexahydro- |
| wln: t6n cn entj a2 c2 e2 |
| s-triazine,3,5-triethyl- |
| 7779-27-3 |
| nsc26771 |
| s-triazine,3,5-triethylhexahydro- |
| vancide th |
| triethyl-trimethylenetriamine |
| 1,5-triazine, 1,3,5-triethylhexahydro- |
| 1,5-triethylhexahydro-1,3,5-triazine |
| nsc-26771 |
| hexahydro-1,5-triethyl-s-triazine |
| 1,5-triethylhexahydro-s-triazine |
| 1,3,5-triallylhexahydro-s-triazine |
| 1,3,5-triethyl-1,3,5-triazinane |
| inchi=1/c9h21n3/c1-4-10-7-11(5-2)9-12(6-3)8-10/h4-9h2,1-3h |
| einecs 231-924-4 |
| s-triazine, hexahydro-1,3,5-triethyl- |
| ai3-11120 |
| nsc 26771 |
| hexahydro-1,3,5-triethyl-1,3,5-triazine |
| brn 0106840 |
| vancide-th |
| 1,3,5-triethylhexahydro-s-triazine |
| hexahydro-1,3,5-triethyl-s-triazine |
| 1,3,5-triethylhexahydro-1,3,5-triazine |
| FT-0690849 |
| unii-t5ada431cf |
| t5ada431cf , |
| 4-26-00-00004 (beilstein handbook reference) |
| NCGC00255144-01 |
| dtxsid1032511 , |
| tox21_301622 |
| cas-7779-27-3 |
| dtxcid9012511 |
| AKOS015913568 |
| triethylhexahydro-s-triazine, 1,3,5- |
| triethyltrimethylenetriamine |
| 1,3,5-triazine,1,3,5-triethylhexahydro- |
| SCHEMBL407168 |
| 1,3,5-triethylhexahydro-sym-triazine |
| 1,3,5-triethyl-1,3,5-triazinane # |
| XYRTVIAPRQLSOW-UHFFFAOYSA-N |
| CHEMBL3188974 |
| Q27289695 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Since the acute dermal LD50 closely approximated the acute oral LD50 in rats, this route might constitute the most serious hazard involved with V-TH and special precautions should be exercised when handling or using this substance." | ( Acute and subacute toxicology and safety evaluation of hexahydro-1,3,5-triethyl-S-triazine. Davis, ER; Fochtman, FW; McClain, RM; Shanor, SP; Winek, CL, ) | 0.38 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Skin sections were dosed topically with aqueous mixtures containing mineral oil or polyethylene glycol (PEG) spiked with (14)C-triazine." | ( Pre-treatment effects of trichloroethylene on the dermal absorption of the biocide, triazine. Baynes, RE; Brooks, JD; Riviere, JE; Yeatts, JL, 2005) | 0.33 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 46.7855 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 74.1500 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||